These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7672436)

  • 41. Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).
    Cheng L; Quek CY; Hung LW; Sharples RA; Sherratt NA; Barnham KJ; Hill AF
    Sci Rep; 2016 Mar; 6():22398. PubMed ID: 26928495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
    Segura-Aguilar J; Kostrzewa RM
    Neurotox Res; 2015 Apr; 27(3):328-54. PubMed ID: 25631236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Animal models of Parkinson's disease: An updated overview.
    Gubellini P; Kachidian P
    Rev Neurol (Paris); 2015 Nov; 171(11):750-61. PubMed ID: 26343921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
    Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
    [No Abstract]   [Full Text] [Related]  

  • 45. Do environmental toxins cause Parkinson's disease? A critical review.
    Tanner CM; Langston JW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 17-30; discussion 30-1. PubMed ID: 2215971
    [No Abstract]   [Full Text] [Related]  

  • 46. Glutamate and Parkinson's disease.
    Greenberg DA
    Ann Neurol; 1994 Jun; 35(6):639. PubMed ID: 7911652
    [No Abstract]   [Full Text] [Related]  

  • 47. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Mounsey RB; Mustafa S; Robinson L; Ross RA; Riedel G; Pertwee RG; Teismann P
    Exp Neurol; 2015 Nov; 273():36-44. PubMed ID: 26244281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
    Zimin IA; Kapitsa IG; Voronina TA; Kovalev GI
    Eksp Klin Farmakol; 2010 Nov; 73(11):2-5. PubMed ID: 21254589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
    Cheng FC; Ni DR; Wu MC; Kuo JS; Chia LG
    Neurosci Lett; 1998 Aug; 252(2):87-90. PubMed ID: 9756328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pesticide-Parkinson link explored.
    Bonetta L
    Nat Med; 2002 Oct; 8(10):1050. PubMed ID: 12357226
    [No Abstract]   [Full Text] [Related]  

  • 51. LRRK2 mutations and neurotoxicant susceptibility.
    Lee JW; Cannon JR
    Exp Biol Med (Maywood); 2015 Jun; 240(6):752-9. PubMed ID: 25888648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Dluzen D; Jain R; Liu B
    J Neurochem; 1994 Jan; 62(1):94-101. PubMed ID: 8263548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gangliosides and parkinsonism.
    Herrero MT; Kastner A; Perez-Otaño I; Hirsch EC; Luquin MR; Javoy-Agid F; Del Río J; Obeso JA; Agid Y
    Neurology; 1993 Oct; 43(10):2132-4. PubMed ID: 8413979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural toxin implicated as triggering Parkinson's disease.
    Pak J Biol Sci; 2011 Feb; 14(3):255. PubMed ID: 21870660
    [No Abstract]   [Full Text] [Related]  

  • 55. New marker for nerve damage.
    Stone R
    Science; 1993 Mar; 259(5101):1541. PubMed ID: 8456282
    [No Abstract]   [Full Text] [Related]  

  • 56. Environment, genetics and idiopathic Parkinson's disease.
    Poirier J; Kogan S; Gauthier S
    Can J Neurol Sci; 1991 Feb; 18(1):70-6. PubMed ID: 2036620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
    J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069
    [No Abstract]   [Full Text] [Related]  

  • 58. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.
    Bretaud S; Lee S; Guo S
    Neurotoxicol Teratol; 2004; 26(6):857-64. PubMed ID: 15451049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine.
    Wilkening D; Vernier VG; Arthaud LE; Treacy G; Kenney JP; Nickolson VJ; Clark R; Smith DH; Smith C; Boswell G
    Brain Res; 1986 Mar; 368(2):239-46. PubMed ID: 3697724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.